% | $
Quotes you view appear here for quick access.

International Business Machines Corporation Message Board

lws2000 197 posts  |  Last Activity: 4 hours ago Member since: Nov 21, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Dr. Tefferi's presentation at ASH will be one for the medical-history books.

  • This is the "Perfect Storm". The "good-news" has been there for awhile, but the confirmations were not in place. These 3 conferences will remove all questions about IMET's effectiveness, safety and potential.

  • Reply to

    ASH will be the "corner-turned" for IMET

    by lws2000 Nov 25, 2015 6:04 PM

    It looks like the combination of Mayo Clinic, JNJ/Janssen, NEJM, and ASH will finally drive the PPS over $5 where many new institutions can invest in Geron. The medical news and the scientific news have been first-class-positive. There has been no negative news so far. With ODD approvals (both FDA & EU) already granted, upgraded approvals seem likely worldwide for IMET.

  • Reply to

    FDA hold was bogus, let's break $5. this week.

    by mangymutt Nov 29, 2015 9:42 PM
    lws2000 lws2000 Nov 29, 2015 11:26 PM Flag

    That is true. IMET was so good (at Mayo Clinic) that he was caught by surprise, and did not have the complete or proper data. He (Dr. S) knew at that point that he was way over his head, and began listening to Dr. T, who started to wear two hats (Mayo & Geron). Together they found JNJ/Janssen, a major oncology company, as the new senior partner, and a "heavyweight" with the FDA. Dr. T still wears two hats (Mayo and Janssen now). Dr. T is now leading JNJ's 80 or so trial sites, and will present at ASH (Dec. 5). We all expect good news and FDA approvals beyond ODD.

  • This company has two headquarters: USA & Israel. It specializes in both corporate and military software. It has had solid earnings for many years.

  • Reply to

    NO GERN PIPER J. CONFERENCE--all a lie !!!

    by incar92 Nov 29, 2015 12:31 PM
    lws2000 lws2000 Nov 29, 2015 12:53 PM Flag

    The Big News and Focus are at ASH (Dec. 5). PJ conference is Dec. 2. They almost overlap.

  • Reply to

    ASH will be the "corner-turned" for IMET

    by lws2000 Nov 25, 2015 6:04 PM
    lws2000 lws2000 Nov 26, 2015 11:02 AM Flag

    ASH, IMO, will be the event that will finally drive the Geron PPS above $5.

  • After ASH the world will be aware of what successes IMET has achieved (especially in the blood cancers), and its potential. Geron's PPS has not been tied to or correlated to either IMET's successes or its potential as described by Mayo Clinic and implemented at 80 or so international trial sites (JNJ/Janssen). IMO, ASH is about to change that.

  • lws2000 lws2000 Nov 25, 2015 6:39 AM Flag

    Cybersecurity can be divided into 5 parts:

    1. Corporate
    2. Nation
    3. Criminal
    4. Terrorist
    5. Individual hackers

    These areas are growing and will continue to grow. FEYE is well positioned to defend against these threats.

  • lws2000 lws2000 Nov 24, 2015 11:40 PM Flag

    IMET is a launching platform for a number of drugs.

  • Reply to

    Can Share Price withstand any more "GOOD NEWS"

    by mwb678 Nov 24, 2015 8:48 AM
    lws2000 lws2000 Nov 24, 2015 2:08 PM Flag

    The earnings were disappointing, but they were limited by growing pains and investment in the cybersecurity future. It looks like a good investment at these prices.

  • lws2000 lws2000 Nov 23, 2015 12:03 PM Flag

    Europe is in complete panic with both the immigrant invasions and the Paris massacres. ISIS seems to have mastered the "dark web".

  • Merck Kommanditgesellschaft auf Aktien discovers, develops, manufactures, and markets pharmaceutical and chemical products worldwide. The company provides pharmaceutical and biological prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and cardiovascular and metabolic diseases; fertility drugs for every stage of the reproductive cycle; hypoallergenic products for specific immunotherapy and diagnosis of type 1 allergies; and biosimilars focusing on oncology and inflammatory disorders. It also manufactures and markets over-the-counter pharmaceuticals to address mobility, women’s and children’s health, cough and cold, and everyday health protection under the Neurobion, Bion, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brand names. In addition, the company offers life science tools and technologies for use in the research, development, and manufacture of biotechnological and pharmaceutical drug therapies, as well as in research and application laboratories. Further, it provides specialty chemicals that are used in various end products, including liquid crystals for displays; LED materials for lighting, as well as organic light-emitting diode materials for lighting and displays; functional materials for solar panels and energy solutions; effect pigments, as well as active ingredients and fillers for cosmetics, food, and pharmaceutical products; pigments and functional materials for coatings, printing, and plastics; and specialty chemical materials for the electronics industry. Merck Kommanditgesellschaft auf Aktien was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

  • lws2000 lws2000 Nov 21, 2015 2:43 PM Flag

    When the fat lady sings (FDA grants advanced approval for IMET) the PPS immediately goes to $10, IMO. Some other country or the EU may get there first.

  • lws2000 lws2000 Nov 20, 2015 12:07 PM Flag

    If we are correct, this has been a buildup to ASH, where all of the science, medical successes and medical potential will come together. The international publicity should increase "investors value", since cancer treatments of this significance are few and far between. Without JNJ as a partner, investor, trial organizer and leader, I doubt if IMET or Geron could have gotten off of the ground. Geron would have been crushed by the hedge funds, and those companies that influenced the FDA (remember the liver-holds) in negative ways. "Chippy" and Dr. T are now part of the JNJ team. JNJ knows how to satisfy the FDA, the EU equivalent and other approval agencies.

  • SANTA ROSA, Calif. (AP) _ Keysight Technologies Inc. (KEYS) on Thursday reported fiscal fourth-quarter earnings of $277 million.

    On a per-share basis, the Santa Rosa, California-based company said it had net income of $1.61. Earnings, adjusted for one-time gains and costs, came to 71 cents per share.

    The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 63 cents per share.

    The electronic measurement technology company posted revenue of $750 million in the period, which also topped Street forecasts. Three analysts surveyed by Zacks expected $747.3 million.

    For the year, the company reported profit of $513 million, or $3 per share. Revenue was reported as $2.86 billion.

  • The opera is over and IMET has won. We are waiting for the fat lady to sing. There is nothing that can stop IMET as a medicine, and Geron's PPS can only be held down by market manipulation and corruption. IMET is just too good.

    1. World class Nobel Prize science
    2. Unique multi-use successful blood cancer medicine that saves lives
    3. Safety proven

    The FDA and equivalent international organizations know this with ODD status granted in the USA and the EU. Can full approval be far off? There is no way that the science or medical successes can be challenged (Mayo Clinic, NEJM, remissions) at this point in time. ASH looks like a home run with JNJ's leadership.

  • Despite FireEye's slowdown in growth, evident in the company's surprisingly low Q3 billings growth rate of 28%(total Q3 billings of $210.6 million), the company's long-term growth opportunities remain high. With the huge increase in cyberattacks on government entities, corporations, etc., FireEye should continue to see strong demand in the long run. While FireEye has recently lost some momentum on the growth front, this has largely been priced in. In fact, the company lost nearly a quarter of its value after it released his Q3 results. Regardless of the company's recent underperformance, FireEye is still at the forefront of the booming cybersecurity industry.

    FireEye continues to perform well against its peers in terms of direct product competition, which is an indication of the company's exceptional technology. The company is also increasing the value of its individual transactions. In fact, FireEye increased the value of its sales by more than 70% for new logo customers, which suggest that its platform is gaining in popularity. Not surprisingly, FireEye's customers are also renewing services at incredibly high rates.

    With customer growth rates remaining relatively high and value per customer increasing, FireEye is still well-positioned on the growth front. As cybersecurity concerns should continue to escalate in the coming quarters/years, FireEye should enjoy high levels of demand moving forward. Although the decline in billings is certainly worrisome for a growth company like FireEye, the market has already punished the company on this front. (Nov. 7, SA)

  • Reply to

    Let's See

    by irishtrader52 Nov 18, 2015 7:43 PM
    lws2000 lws2000 Nov 19, 2015 10:35 PM Flag

    The opera is over and IMET has won. We are waiting for the fat lady to sing. There is nothing that can stop IMET as a medicine, and Geron's PPS can only be held down by market manipulation and corruption. IMET is just to good.

139.42+0.96(+0.69%)Nov 30 4:02 PMEST